U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399899) titled 'Dose-Finding Study of NBX-100 in Healthy Adult Participants' on Nov. 16, 2025.
Brief Summary: NB-2025 P1 001 is a Phase Ib study that will investigate the pharmacokinetics, pharmacodynamics, safety, tolerability, psychological effects of escalating doses of NBX-100 in healthy volunteers.
A 28-day screening period is followed by a preparation visit with psychologist in Week 1. From Week 2 to Week 5, participants will receive a once weekly dose of study treatment, receiving four doses in total. Participants will attend a follow-up visit each day immediately after each dosing day. In Week 6, participants will attend an integration vis...